Sector News

Allergan's CEO now says a strategic review is happening

March 15, 2018
Life sciences

Just over four months ago, Allergan CEO Brent Saunders told investors in no uncertain terms that a breakup of the company was “not on the table.” But now? All bets are off.

Wednesday at an investor conference, Saunders’ “message was clear that all strategic options are being evaluated,” RBC Capital Markets analyst Randall Stanicky wrote to clients. What’s more, the company is taking on the task “with a sense of urgency,” the analyst said.

“Allergan underscored it has a ‘bias for action’ which we thought was a notable comment,” Stanicky wrote.

During last year’s third-quarter conference call, Saunders assured shareholders that a cost-cutting drive—not a breakup—would be the answer to Allergan’s share-price problems. Shortly thereafter, he and his team laid out plans to trim 1,400 positions to help cut annual costs by $300 million to $400 million.

Since then, though, things have largely gone downhill for the Dublin drugmaker. Its controversial Restasis licensing deal with a Native American tribe—meant to help the blockbuster drug avoid a patent challenge—didn’t work, leaving Allergan’s No. 2 seller vulnerable to that very loss.

As for its No. 1 seller, Botox? Mylan revealed just days later that it would team up with would-be challenger Revance on a biosimilar version of the Allergan blockbuster.

And then came the FDA delay for Esmya, the uterine fibroid treatment Allergan’s working to bring to market. After European regulators announced they’d be reviewing Esmya’s safety, the FDA pushed back its review deadline by three months, buying it time to carry out its own deep dive into the drug’s potential to trigger liver problems.

Meanwhile, Saunders’ Wednesday message was music to Stanicky’s ears. The analyst has long been calling for an Allergan split, positing that business units such as women’s health could fetch up to $6 billion in a sale.

“We expect Street focus on asset sales to now more broadly pick up,” he wrote.

Source: Fierce Pharma

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach